AbbVie
ABBV
ABBV
3,041 hedge funds and large institutions have $195B invested in AbbVie in 2022 Q1 according to their latest regulatory filings, with 234 funds opening new positions, 1,152 increasing their positions, 1,325 reducing their positions, and 124 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
3,041
Holders Change
+73
Holders Change %
+2.46%
% of All Funds
48.12%
Holding in Top 10
296
Holding in Top 10 Change
+83
Holding in Top 10 Change %
+38.97%
% of All Funds
4.68%
New
234
Increased
1,152
Reduced
1,325
Closed
124
Calls
$3.37B
Puts
$3.13B
Net Calls
+$243M
Net Calls Change
-$778M
Top Buyers
| 1 |
Capital International Investors
Los Angeles,
California
|
+$3.06B |
| 2 |
JPMorgan Chase & Co
New York
|
+$1.78B |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$682M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$672M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$611M |
Top Sellers
| 1 |
Franklin Resources
San Mateo,
California
|
-$916M |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$411M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$345M |
| 4 |
Bank of New York Mellon
New York
|
-$256M |
| 5 |
Barclays
London,
United Kingdom
|
-$235M |